CMS Advises LifeWatch regarding Competing Public Takeover Offers
Zurich | In January of this year, Aevis Victoria SA launched a public tender offer for all outstanding shares of LifeWatch AG. LifeWatch is a Swiss stock corporation based in Zug, listed on the SIX Swiss Exchange (LIFE). In the wake of the offer of Aevis Victoria, LifeWatch started an auction process and has been able to secure the US domiciled BioTelemetry, Inc., as a bidder. In April, after having signed a transaction agreement with LifeWatch, BioTelemetry announced a competing public tender offer. On 14 July 2017, BioTelemetry's offer could finally be settled.
LifeWatch is a leading healthcare technology and solution company, specializing in advanced digital health systems and wireless remote diagnostic patient monitoring services. LifeWatch’s services provide physicians with critical information to determine appropriate treatment and thereby improve patient outcomes.
BioTelemetry, formerly known as CardioNet, is a leading wireless medical technology company. The company, domiciled in Malvern, Pennsylvania / USA, is listed on NASDAQ (BEAT).
A team of CMS led by Dr André Lebrecht provided extensive legal advice to LifeWatch in the context of the competing takeover offers of BioTelemetry and Aevis Victoria. CMS demonstrates its expertise in the field of public M&A, including proceedings before the TOB (Swiss takeover board).
The CMS team:
Dr André Lebrecht, Lead Partner
Dr Daniel Jenny, Partner – Corporate / M&A / Capital Markets Law
Dr Stephan Werlen, Partner – Corporate / M&A / Capital Markets Law
Matthias Kuert, Associate – Banking & Finance / Capital Markets Law
Anna Tomaschek, Associate – Corporate / M&A
Florian Jung, Trainee – Corporate / M&A
Valentina Balaj, Trainee – Corporate / M&A
Rade Kokanović, Trainee – Corporate / M&A